Viracta Therapeutics, Inc. Board of Directors

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Mr. Mark Andrew Rothera

Mr. Mark Andrew Rothera

CEO, President & Director

Dr. Douglas V. Faller M.D., Ph.D.

Dr. Douglas V. Faller M.D., Ph.D.

Scientific Founder & Chairman of Scientific Advisory Board

Dr. Ayman El-Guindy

Dr. Ayman El-Guindy

Chief Scientific Officer

Dr. Susan Perrine M.D.

Dr. Susan Perrine M.D.

Scientific Founder and Consultant

Mr. Michael Eric Faerm

Mr. Michael Eric Faerm

Chief Financial Officer

Dr. Ronald J. Berenson M.D.

Dr. Ronald J. Berenson M.D.

Co-Founder and Consultant

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.